BioNTech (NASDAQ:BNTX) Trading Down 1.6% – Here’s Why

Shares of BioNTech SE (NASDAQ:BNTX) dropped 1.6% during mid-day trading on Friday . The company traded as low as $117.76 and last traded at $118.75. Approximately 98,963 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 806,475 shares. The stock had previously closed at $120.69.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Berenberg Bank assumed coverage on BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Finally, BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $140.76.

BioNTech Trading Down 0.2 %

The firm has a market capitalization of $28.64 billion, a P/E ratio of -56.55 and a beta of 0.22. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average is $113.91 and its 200-day moving average is $100.17.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.73 EPS. As a group, sell-side analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Planning Capital Management Corp raised its stake in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the last quarter. Blue Trust Inc. grew its holdings in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of BioNTech in the 3rd quarter valued at $210,000. Finally, Probity Advisors Inc. acquired a new position in shares of BioNTech during the third quarter valued at $216,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.